AIM ImmunoTech
14 hedge funds and large institutions have $1.72M invested in AIM ImmunoTech in 2016 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 1 closing their positions.
0.22% less ownership
Funds ownership: 6.21% → 5.99% (-0.22%)
7% less funds holding
Funds holding: 15 → 14 (-1)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $58.9K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$19.7K |
| 2 |
Virtu KCG Holdings
New York
|
-$13.1K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$12K |
| 4 |
Renaissance Technologies
New York
|
-$6.56K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$6.56K |
AIM Hedge Fund Activity: Q2 2016 in Review
14 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q2 2016, worth a combined $1.72M — down 16% from $2.04M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of AIM and 0 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 0 added.
The largest seller was Citadel Advisors, cutting an estimated $19.7K.
- 14 institutional investors held AIM ImmunoTech (AIM) as of Q2 2016, down from 15 in Q1 2016.
- Funds reported $1.72M of AIM ImmunoTech stock for Q2 2016, down 16% quarter-over-quarter.
- 0 funds opened new AIM ImmunoTech positions in Q2 2016 and 1 closed out, a net change of -1 holder.
- The largest AIM ImmunoTech seller in Q2 2016 was Citadel Advisors, an estimated $19.7K sold.
Based on aggregated 13F filings for Q2 2016.